Existing Annotations Review

GO Term	Evidence	Action	Reason
GO:0005576 extracellular region	IEA GO_REF:0000044	ACCEPT	Summary: NESP55 is a secretory precursor, so extracellular-region annotation is plausible for processed/secreted material but is not the most specific functional compartment. Reason: NESP55 is a secretory precursor and the extracellular-region term is a valid broad location for processed/secreted material, although secretory granule is the more specific intracellular context. Supporting Evidence: PMID:10729789 NESP55 open reading frame encoded a hydrophilic protein file:human/GNAS/GNAS-uniprot.txt May be proteolytically processed to give rise to a number of active peptides.
GO:0030133 transport vesicle	IEA GO_REF:0000044	MODIFY	Summary: Transport vesicle is too generic; the evidence for NESP55 points more specifically to neuroendocrine secretory granules/secretory pathway compartments. Reason: NESP55 is chromogranin-like and shows finely granular cytoplasmic staining in pituitary adenomas, fitting secretory granule biology better than a generic transport vesicle term. Proposed replacements: secretory granule Supporting Evidence: PMID:21584660 marker of the constitutive secretory pathway PMID:21584660 brown finely granular cytoplasmic staining
GO:0071107 response to parathyroid hormone	IEA GO_REF:0000002	MARK AS OVER ANNOTATED	Summary: The PTH-response evidence reflects GNAS-locus imprinting and methylation effects rather than a direct NESP55 protein activity. Reason: PMID:22378814 shows that a deletion removing NESP55 affects imprinting and PHP1B, but this is a regulatory-locus effect. It should not be treated as a core biological process of the NESP55 protein product. Supporting Evidence: PMID:22378814 A novel deletion of 18,988 bp that removes NESP55 PMID:22378814 NESP55 is an additional imprinting
GO:0005886 plasma membrane	IDA GO_REF:0000052	REMOVE	Summary: Plasma membrane is not supported as a normal NESP55 protein location by the reviewed literature; NESP55 is a secretory/granin-like product. Reason: The evidence points to secretory granule/cytoplasmic granular staining and secretion rather than a plasma-membrane resident role. Supporting Evidence: PMID:21584660 brown finely granular cytoplasmic staining
GO:0120162 positive regulation of cold-induced thermogenesis	ISS PMID:20374964 G(s)alpha deficiency in adipose tissue leads to a lean pheno...	REMOVE	Summary: Cold-induced thermogenesis is a Gs-alpha/adipose signaling phenotype and should not be assigned to the NESP55 protein product represented by O95467. Reason: PMID:20374964 studies Gs-alpha deficiency in adipose tissue. That is not evidence for NESP55 acting in cold-induced thermogenesis. Supporting Evidence: PMID:20374964 Gsalpha plays a critical role in adipogenesis in vivo
GO:0005737 cytoplasm	IDA PMID:20862257 Differentiation in neuroblastoma: diffusion-limited hypoxia ...	ACCEPT	Summary: Cytoplasmic localization is supported as broad localization for NESP55-containing secretory granules and cytoplasmic immunostaining. Reason: The term is broad but compatible with the granular cytoplasmic staining seen in pituitary adenomas and neuroendocrine/chromaffin cells. Supporting Evidence: PMID:21584660 brown finely granular cytoplasmic staining
GO:0005634 nucleus	IDA PMID:20862257 Differentiation in neuroblastoma: diffusion-limited hypoxia ...	REMOVE	Summary: Nuclear localization is not supported as a normal NESP55 location in the reviewed sources. Reason: The main evidence supports cytoplasmic secretory granule/neuroendocrine localization, not nuclear residence. Supporting Evidence: PMID:20862257 NESP55 is a highly specific marker for chromaffin cell types during development
GO:0040015 negative regulation of multicellular organism growth	ISS GO_REF:0000024	REMOVE	Summary: Negative regulation of organism growth is a broad GNAS-locus/Gs-alpha phenotype and not a direct NESP55 function. Reason: The NESP55 product is a chromogranin-like secretory precursor; growth phenotypes from GNAS models should not be propagated to this product without product-specific evidence. Supporting Evidence: file:human/GNAS/GNAS-deep-research-falcon_artifacts/artifact-00.md NESP55 should not be conflated with canonical Gsalpha signaling protein products.
GO:0048471 perinuclear region of cytoplasm	IDA PMID:21584660 Immunohistochemical expression of neuroendocrine secretory p...	KEEP AS NON CORE	Summary: Perinuclear cytoplasmic localization is plausible for secretory-pathway/granular staining but is not the core location term. Reason: NESP55 is associated with neuroendocrine secretory compartments; perinuclear cytoplasm can be retained as broad localization evidence. Supporting Evidence: PMID:21584660 brown finely granular cytoplasmic staining
GO:0071107 response to parathyroid hormone	IMP PMID:22378814 A new deletion ablating NESP55 causes loss of maternal impri...	MARK AS OVER ANNOTATED	Summary: The PTH-response evidence reflects GNAS-locus imprinting and methylation effects rather than a direct NESP55 protein activity. Reason: PMID:22378814 shows that a deletion removing NESP55 affects imprinting and PHP1B, but this is a regulatory-locus effect. It should not be treated as a core biological process of the NESP55 protein product. Supporting Evidence: PMID:22378814 A novel deletion of 18,988 bp that removes NESP55 PMID:22378814 NESP55 is an additional imprinting
GO:0007565 female pregnancy	NAS PMID:10729789 Neuroendocrine secretory protein 55 (NESP55): alternative sp...	REMOVE	Summary: Female pregnancy is not supported as a direct process for the NESP55 protein product. Reason: The cited NESP55 cloning/processing paper describes a neuroendocrine secretory protein and tissue-specific splicing, not a direct pregnancy function. Supporting Evidence: PMID:10729789 NESP55 open reading frame encoded a hydrophilic protein
GO:0009306 protein secretion	NAS PMID:10729789 Neuroendocrine secretory protein 55 (NESP55): alternative sp...	MARK AS OVER ANNOTATED	Summary: NESP55 is a secretory protein/cargo, but the available evidence does not show that it actively mediates protein secretion. Reason: A secreted or processed cargo should not automatically receive a protein secretion process annotation as if it controls secretion machinery. Supporting Evidence: PMID:10729789 posttranslational processing of a maternally expressed protein PMID:21584660 marker of the constitutive secretory pathway

Core Functions

NESP55 acts as a chromogranin-like neuroendocrine secretory precursor in chromaffin/neuroendocrine cells, undergoing post-translational processing and marking secretory-granule differentiation rather than catalyzing a defined biochemical reaction.

Cellular Locations:

secretory granule extracellular region

Supporting Evidence:

PMID:10729789
NESP55 open reading frame encoded a hydrophilic protein
PMID:10729789
posttranslational processing of a maternally expressed protein
PMID:21584660
marker of the constitutive secretory pathway
PMID:20862257
NESP55 is a highly specific marker for chromaffin cell types during development

References

GO_REF:0000002

Gene Ontology annotation through association of InterPro records with GO terms

GO_REF:0000024

Manual transfer of experimentally-verified manual GO annotation data to orthologs by curator judgment of sequence similarity

GO_REF:0000044

Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location vocabulary mapping, accompanied by conservative changes to GO terms applied by UniProt

GO_REF:0000052

Gene Ontology annotation based on curation of immunofluorescence data

PMID:10729789

Neuroendocrine secretory protein 55 (NESP55): alternative splicing onto transcripts of the GNAS gene and posttranslational processing of a maternally expressed protein.

PMID:20374964

G(s)alpha deficiency in adipose tissue leads to a lean phenotype with divergent effects on cold tolerance and diet-induced thermogenesis.

PMID:20862257

Differentiation in neuroblastoma: diffusion-limited hypoxia induces neuro-endocrine secretory protein 55 and other markers of a chromaffin phenotype.

PMID:21584660

Immunohistochemical expression of neuroendocrine secretory protein-55 (NESP-55) in pituitary adenomas.

PMID:22378814

A new deletion ablating NESP55 causes loss of maternal imprint of A/B GNAS and autosomal dominant pseudohypoparathyroidism type Ib.

file:human/GNAS/GNAS-uniprot.txt

UniProt record for GNAS/NESP55

file:human/GNAS/GNAS-deep-research-falcon_artifacts/artifact-00.md

Falcon deep research artifact for GNAS/NESP55

Suggested Experiments

Experiment: Use isoform/product-specific antibodies or tagged endogenous NESP55 to define secretory granule localization and secretion dynamics in neuroendocrine cells.

Hypothesis: NESP55 will localize to regulated secretory compartments and be secreted or processed in neuroendocrine cells.

Experiment: Profile processed NESP55 peptides by targeted mass spectrometry in pituitary, adrenal medulla, and neuroendocrine tumor samples.

Hypothesis: Product-specific peptide profiling will identify which NESP55-derived peptides are reproducibly produced in relevant tissues.

Deep Research

Falcon

(GNAS-deep-research-falcon.md)

this with annotations you find in gene/protein databases, but these can be outdated or inaccurate. Falcon Edison Scientific Literature 23 citations 2 artifacts 2026-06-02T20:43:45.220980

Edison artifact artifact-00 (text/markdown)

## Context ID: pqac-00000010 The main schematic figure of the GNAS locus and its imprinting control regions (ICRs) is shown in Figure 1A. This diagram illustrat (image/png)

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research Report: Human GNAS locus product NESP55 (UniProt O95467)—functional annotation

0) Target verification (critical disambiguation)

The UniProt accession O95467 corresponds to Neuroendocrine secretory protein 55 (NESP55), a neuroendocrine secretory/granin-like protein produced from the human imprinted GNAS locus and distinct from the canonical stimulatory G-protein α subunit Gsα (which is encoded by different GNAS exons and functions in GPCR–cAMP signaling). (fonin2019multifunctionalityofproteins pages 15-17, yang2023gnaslocusbone pages 1-2)

A key distinction is transcript architecture and imprinting: NESP55 uses its own upstream promoter/first exon (NESP55 exon) and is expressed from the maternal allele, whereas Gsα is generally biallelic (with tissue-specific paternal silencing) and is encoded by the shared GNAS coding exons 1–13. (iwasaki2023thelongrangeinteraction pages 1-2, yang2023gnaslocusbone pages 1-2, raut2025contracttokill pages 1-3)

1) Key concepts and current definitions

1.1 The GNAS locus as a “complex/imprinted” gene

Recent and authoritative sources describe GNAS as a complex locus with multiple products initiated from different promoters/first exons, including Gsα, XLαs, A/B, antisense transcripts, and NESP55, each with distinct imprinting patterns. (raut2025contracttokill pages 1-3, iwasaki2023thelongrangeinteraction pages 1-2, yang2023gnaslocusbone pages 1-2, cipriano2024genotype–phenotypecorrelationof pages 1-2)

Figure evidence (locus concept): A schematic of the GNAS locus showing NESP55, Gsα, other transcripts, and differentially methylated regions (DMRs)/imprinting control regions (ICRs) is provided in Iwasaki et al. (JCI, 2023). (iwasaki2023thelongrangeinteraction media 2311e80e)

1.2 What NESP55 is (and is not)

NESP55 is best understood as a chromogranin/granin-like neuroendocrine secretory precursor protein, rather than an enzyme, transporter, or canonical signal transducer such as Gsα. (bastepe2007thegnaslocus pages 13-13, bastepe2007thegnaslocus pages 1-2)

A structural feature consistent with granin-like behavior is its high predicted intrinsic disorder: one structure–function review reports NESP55 is highly intrinsically disordered (high predicted disorder fraction) and shares no sequence similarity with other GNAS isoforms, emphasizing that “GNAS” literature about Gsα cannot be assumed to apply to NESP55. (fonin2019multifunctionalityofproteins pages 15-17)

2) Molecular function: biochemical nature, processing, and inferred mechanism

2.1 Precursor and peptide processing

Older but authoritative review-level synthesis reports NESP55 was cloned as a novel chromogranin-like precursor and undergoes post-translational processing into peptides; one processed peptide was reported to have 5‑HT1B receptor antagonist activity. (bastepe2007thegnaslocus pages 13-13)

Interpretation (current understanding): based on available evidence, NESP55’s primary molecular role is most consistent with being a regulated secretory pathway cargo/precursor that can be processed into bioactive peptides, rather than performing a defined catalytic reaction. (bastepe2007thegnaslocus pages 13-13)

2.2 Subcellular localization and secretion context

NESP55 has been reported to localize preferentially in neuroendocrine secretory cell types, including adrenal medulla adrenaline-synthesizing cells, consistent with localization to neuroendocrine secretory compartments (e.g., secretory granules) characteristic of granin-family proteins. (bastepe2007thegnaslocus pages 13-13)

3) Expression and localization in tissues (current evidence)

NESP55 is described as a neuroendocrine-enriched product; a 2024 clinical marker paper summarizes reported presence in chromaffin cells, pituitary, and neuroendocrine tumors such as pheochromocytoma, neuroblastoma, and pancreatic neuroendocrine tumors (including insulinoma). (юкина2024поискновыхиммуногистохимических pages 2-3)

4) Pathways and regulatory biology (recent developments prioritized)

4.1 Imprinting control of NESP55 (2023 mechanistic advance)

A key 2023 mechanistic study using human embryonic stem cell models identified long-range regulatory logic at GNAS:
- The NESP imprinting control region (NESP‑ICR) is required for maternal allele methylation/transcriptional silencing at the A/B region.
- The STX16‑ICR functions as a long-range enhancer of NESP55 transcription in an embryonic-stage-specific manner. (iwasaki2023thelongrangeinteraction pages 1-2)

This work reframes NESP55 not only as a secretory precursor protein, but also as a transcript whose proper expression is integral to establishing/maintaining GNAS imprinting states. (iwasaki2023thelongrangeinteraction pages 1-2)

4.2 NESP55/NESPAS region variants and pseudohypoparathyroidism type 1B (2024 genetic advance)

A 2024 JCI Insight study identified recurrent small variants in the NESP55/NESPAS region in families with broad GNAS methylation defects causing pseudohypoparathyroidism type 1B, and reported that AS (antisense) transcripts were increased while NESP was decreased in cells from affected patients, supporting a mechanistic link between variants near NESP55/NESPAS and altered imprinting/transcription. (li2024recurrentsmallvariants pages 1-2)

5) Current applications and real-world implementations

5.1 Tumor marker exploration in pancreatic neuroendocrine tumors (P‑NETs) and insulinoma

A 2024 insulinoma-focused study (Problems of Endocrinology; n=41, with extended IHC in n=10) evaluated multiple candidate circulating and tissue markers, including NESP55. It reported that circulating marker levels overall did not change significantly post-surgery and that marker expression did not correlate with aggressiveness; the authors concluded that NESP55 was not supported as a promising marker in their dataset. (юкина2024поискновыхиммуногистохимических pages 1-2)

In contrast, the same 2024 paper cites a prior study reporting NESP55 immunoreactivity in 90.9% of P‑NETs, illustrating that NESP55 may show high IHC positivity in some P‑NET cohorts but may not generalize as a clinically useful circulating/tissue marker for insulinoma aggressiveness in all settings. (юкина2024поискновыхиммуногистохимических pages 2-3, юкина2024поискновыхиммуногистохимических pages 1-2)

5.2 Clinical genetics / diagnostics relevance via imprinting

Although much of clinical GNAS genetics focuses on Gsα, recent human studies implicate the NESP55-region imprinting machinery in disease mechanisms (e.g., pseudohypoparathyroidism type 1B through methylation defects involving DMRs connected to NESP). (iwasaki2023thelongrangeinteraction pages 1-2, li2024recurrentsmallvariants pages 1-2)

6) Relevant statistics and recent data points (explicitly evidenced)

90.9%: NESP55 immunoreactivity in pancreatic neuroendocrine tumors (P‑NETs) reported by a cited study in a 2024 insulinoma marker paper. (юкина2024поискновыхиммуногистохимических pages 2-3)
n=41 insulinoma patients; n=10 with extended immunohistochemistry in the 2024 marker evaluation; NESP55 not supported as a promising marker in that cohort. (юкина2024поискновыхиммуногистохимических pages 1-2)

7) Expert synthesis and evidence gaps

Across recent literature, the dominant 2023–2024 advances relevant to NESP55 are regulatory (imprinting control elements, enhancer logic, and disease-associated methylation/transcriptional shifts) rather than new protein biochemistry. (iwasaki2023thelongrangeinteraction pages 1-2, li2024recurrentsmallvariants pages 1-2)

Direct, modern (2023–2024) experimental evidence in the retrieved set remains limited regarding:
- precise human subcellular localization at high resolution,
- proteolytic processing sites/peptide repertoire in humans,
- validated receptor targets and mechanisms for NESP55-derived peptides.
Accordingly, the most defensible functional annotation from the current evidence is that NESP55 is a maternally expressed, granin-like secretory precursor whose transcriptional regulation is embedded within the GNAS imprinting network. (bastepe2007thegnaslocus pages 13-13, iwasaki2023thelongrangeinteraction pages 1-2)

Evidence summary table

Aspect	Key points	Evidence & notes (paper, year)	Citation ID
Identity / exon structure / imprinting	UniProt O95467 corresponds to NESP55, a distinct protein product of the human GNAS locus rather than Gsα. It is produced from its own upstream promoter/first exon and is maternally expressed because the NESP promoter/DMR is methylated on the paternal allele.	Explicitly identified as “NESP55 (UniProt ID: O95467)” and described as transcriptionally/structurally distinct from Gsα; multiple GNAS reviews and primary studies state NESP55 is a separate imprinted GNAS product with maternal expression (Fonin et al., 2019; Iwasaki et al., 2023; Yang et al., 2023; Cipriano et al., 2024).	(fonin2019multifunctionalityofproteins pages 15-17, iwasaki2023thelongrangeinteraction pages 1-2, yang2023gnaslocusbone pages 1-2, cipriano2024genotype–phenotypecorrelationof pages 1-2)
Identity / exon structure / imprinting	The GNAS locus is complex and produces multiple products (Gsα, XLαs, A/B, antisense transcripts, NESP55). NESP55 should not be conflated with canonical Gsα signaling protein products.	Recent reviews and mechanistic studies emphasize distinct promoters/first exons and different imprinting patterns across GNAS products; Figure 1A in Iwasaki et al. schematizes NESP55 separately from Gsα and other transcripts (Iwasaki et al., 2023).	(raut2025contracttokill pages 1-3, iwasaki2023thelongrangeinteraction pages 1-2, yang2023gnaslocusbone pages 1-2, iwasaki2023thelongrangeinteraction media 2311e80e)
Biochemical nature & processing	NESP55 is a chromogranin-like/neuroendocrine secretory precursor rather than an enzyme or transporter. It undergoes post-translational processing to smaller peptides.	Review summarizing foundational cloning/biochemistry describes NESP55 as a “novel chromogranin-like precursor” that is post-translationally processed into peptides; one processed peptide was reported to have 5-HT1B antagonist activity (Bastepe, 2007, citing earlier primary work).	(bastepe2007thegnaslocus pages 13-13)
Biochemical nature & processing	NESP55 is highly intrinsically disordered relative to Gsα isoforms, consistent with granin/secretory precursor behavior.	Structure-function review reports NESP55 has high predicted disorder (~86.5% PDR) and no sequence similarity to other GNAS isoforms, reinforcing that it is biochemically distinct from G protein α-subunits (Fonin et al., 2019).	(fonin2019multifunctionalityofproteins pages 15-17)
Localization	NESP55 localizes to neuroendocrine secretory compartments and is associated with chromogranin-like granules/regulated secretion rather than plasma membrane signal transduction.	Bastepe review summarizes localization studies showing preferential localization in adrenaline-synthesizing cells of bovine and rat adrenal medulla, consistent with secretory granules and a neuroendocrine secretory role (Bastepe, 2007).	(bastepe2007thegnaslocus pages 13-13)
Expression / tissues	NESP55 is a neuroendocrine-enriched product; reported in adrenal medulla/chromaffin cells and other neuroendocrine tissues/tumors.	Review and biomarker literature note presence in chromaffin cells, pituitary, pheochromocytoma tissue, neuroblastomas, insulinomas, and other pancreatic neuroendocrine tumors; older tissue-distribution work in bovine tissues is summarized by Bastepe (2007), and Yukina et al. (2024) reiterate neuroendocrine distribution.	(bastepe2007thegnaslocus pages 13-13, юкина2024поискновыхиммуногистохимических pages 2-3)
Physiology / functional inference	NESP55 is not assigned a canonical catalytic reaction; current understanding supports a role as a regulated secretory-granule precursor within neuroendocrine cells.	The available evidence supports precursor/secretory function and peptide generation, while recent GNAS-locus papers focus mainly on imprinting control rather than direct molecular mechanism of NESP55 action (Bastepe, 2007; Iwasaki et al., 2023; Li et al., 2024).	(bastepe2007thegnaslocus pages 13-13, iwasaki2023thelongrangeinteraction pages 1-2, li2024recurrentsmallvariants pages 1-2)
Disease / clinical relevance	NESP55 transcript regulation matters clinically through GNAS imprinting disorders: reduced NESP expression and altered antisense transcription are implicated in pseudohypoparathyroidism type 1B with broad GNAS methylation defects.	Li et al. (2024) identified recurrent small variants in the NESP55/NESPAS region in affected families and observed increased antisense transcripts with decreased NESP expression in patient cells, linking NESP55-region disruption to PHP1B pathogenesis.	(li2024recurrentsmallvariants pages 1-2)
Disease / clinical relevance	NESP55 has been explored as a neuroendocrine tumor marker, but evidence is mixed and context-dependent.	Yukina et al. (2024) note a prior study reporting NESP55 immunoreactivity in 90.9% of pancreatic neuroendocrine tumors, but in their own insulinoma cohort NESP55 was not supported as a promising tissue/circulating marker.	(юкина2024поискновыхиммуногистохимических pages 2-3, юкина2024поискновыхиммуногистохимических pages 1-2)
Disease / clinical relevance	In a 2024 insulinoma study, NESP55 did not show convincing value for association with insulin-producing tumors or aggressiveness.	Cohort size was 41 patients, with extended IHC in 10; marker levels before surgery and 2–12 months after surgery did not change significantly overall, and NESP55 was among markers not supported for further study in insulinoma (Yukina et al., 2024).	(юкина2024поискновыхиммуногистохимических pages 1-2)
Recent 2023–2024 developments	Major recent advances concern the regulatory biology of the NESP55 region within GNAS imprinting rather than new protein-level biochemistry.	Iwasaki et al. (2023) showed the STX16-ICR acts as a long-range enhancer of maternal NESP55 transcription and that the NESP-ICR is required for A/B methylation/silencing; Li et al. (2024) connected recurrent NESP55/NESPAS-region variants to broad GNAS methylation defects in PHP1B.	(iwasaki2023thelongrangeinteraction pages 1-2, li2024recurrentsmallvariants pages 1-2)

Table: This table summarizes evidence-backed functional annotation for human NESP55 (GNAS; UniProt O95467), including identity, processing, localization, expression, and clinical relevance. It emphasizes what is directly supported by the retrieved literature, especially 2023-2024 studies on GNAS imprinting and biomarker use.

Key references (with URLs and publication dates)

Iwasaki Y. et al. The long-range interaction between two GNAS imprinting control regions delineates pseudohypoparathyroidism type 1B pathogenesis. Journal of Clinical Investigation. Apr 2023. https://doi.org/10.1172/jci167953 (iwasaki2023thelongrangeinteraction pages 1-2, iwasaki2023thelongrangeinteraction media 2311e80e)
Yang W. et al. GNAS locus: bone related diseases and mouse models. Frontiers in Endocrinology. Oct 2023. https://doi.org/10.3389/fendo.2023.1255864 (yang2023gnaslocusbone pages 1-2, yang2023gnaslocusbone pages 12-13)
Li D. et al. Recurrent small variants in NESP55/NESPAS associated with broad GNAS methylation defects and pseudohypoparathyroidism type 1B. JCI Insight. Dec 2024. https://doi.org/10.1172/jci.insight.185874 (li2024recurrentsmallvariants pages 1-2)
Cipriano L. et al. Genotype–Phenotype Correlation of GNAS Gene: Review and Disease Management of a Hotspot Mutation. International Journal of Molecular Sciences. Oct 2024. https://doi.org/10.3390/ijms252010913 (cipriano2024genotype–phenotypecorrelationof pages 1-2)
Yukina M.Y. et al. Поиск новых иммуногистохимических и циркулирующих маркеров инсулиномы (Search for new IHC and circulating markers of insulinoma). Problems of Endocrinology. May 2024. https://doi.org/10.14341/probl13466 (юкина2024поискновыхиммуногистохимических pages 2-3, юкина2024поискновыхиммуногистохимических pages 1-2)
Bastepe M. The GNAS Locus: Quintessential Complex Gene Encoding Gsα, XLαs, and other Imprinted Transcripts. Current Genomics. Sep 2007. https://doi.org/10.2174/138920207783406488 (bastepe2007thegnaslocus pages 13-13, bastepe2007thegnaslocus pages 1-2)
Fonin A.V. et al. Multi-functionality of proteins involved in GPCR and G protein signaling… Cellular and Molecular Life Sciences. Aug 2019. https://doi.org/10.1007/s00018-019-03276-1 (fonin2019multifunctionalityofproteins pages 15-17)

References

(fonin2019multifunctionalityofproteins pages 15-17): Alexander V. Fonin, April L. Darling, Irina M. Kuznetsova, Konstantin K. Turoverov, and Vladimir N. Uversky. Multi-functionality of proteins involved in gpcr and g protein signaling: making sense of structure–function continuum with intrinsic disorder-based proteoforms. Cellular and Molecular Life Sciences, 76:4461-4492, Aug 2019. URL: https://doi.org/10.1007/s00018-019-03276-1, doi:10.1007/s00018-019-03276-1. This article has 78 citations and is from a domain leading peer-reviewed journal.
(yang2023gnaslocusbone pages 1-2): Wan Yang, Yiyi Zuo, Nuo Zhang, Kangning Wang, Runze Zhang, Ziyi Chen, and Qing He. Gnas locus: bone related diseases and mouse models. Frontiers in Endocrinology, Oct 2023. URL: https://doi.org/10.3389/fendo.2023.1255864, doi:10.3389/fendo.2023.1255864. This article has 19 citations.
(iwasaki2023thelongrangeinteraction pages 1-2): Yorihiro Iwasaki, Cagri Aksu, Monica Reyes, Birol Ay, Qing He, and Murat Bastepe. The long-range interaction between two gnas imprinting control regions delineates pseudohypoparathyroidism type 1b pathogenesis. Journal of Clinical Investigation, Apr 2023. URL: https://doi.org/10.1172/jci167953, doi:10.1172/jci167953. This article has 25 citations and is from a highest quality peer-reviewed journal.
(raut2025contracttokill pages 1-3): Pratima Raut, Poompozhil Mathivanan, Surinder K. Batra, and Moorthy P. Ponnusamy. Contract to kill: gnas mutation. Molecular Cancer, Mar 2025. URL: https://doi.org/10.1186/s12943-025-02247-4, doi:10.1186/s12943-025-02247-4. This article has 5 citations and is from a highest quality peer-reviewed journal.
(cipriano2024genotype–phenotypecorrelationof pages 1-2): Lorenzo Cipriano, Rosario Ferrigno, Immacolata Andolfo, Roberta Russo, Daniela Cioffi, Maria Cristina Savanelli, Valeria Pellino, Antonella Klain, Achille Iolascon, and Carmelo Piscopo. Genotype–phenotype correlation of gnas gene: review and disease management of a hotspot mutation. International Journal of Molecular Sciences, 25:10913, Oct 2024. URL: https://doi.org/10.3390/ijms252010913, doi:10.3390/ijms252010913. This article has 1 citations.
(iwasaki2023thelongrangeinteraction media 2311e80e): Yorihiro Iwasaki, Cagri Aksu, Monica Reyes, Birol Ay, Qing He, and Murat Bastepe. The long-range interaction between two gnas imprinting control regions delineates pseudohypoparathyroidism type 1b pathogenesis. Journal of Clinical Investigation, Apr 2023. URL: https://doi.org/10.1172/jci167953, doi:10.1172/jci167953. This article has 25 citations and is from a highest quality peer-reviewed journal.
(bastepe2007thegnaslocus pages 13-13): Murat Bastepe. The gnas locus: quintessential complex gene encoding gsα, xlαs, and other imprinted transcripts. Current Genomics, 8:398-414, Sep 2007. URL: https://doi.org/10.2174/138920207783406488, doi:10.2174/138920207783406488. This article has 82 citations and is from a peer-reviewed journal.
(bastepe2007thegnaslocus pages 1-2): Murat Bastepe. The gnas locus: quintessential complex gene encoding gsα, xlαs, and other imprinted transcripts. Current Genomics, 8:398-414, Sep 2007. URL: https://doi.org/10.2174/138920207783406488, doi:10.2174/138920207783406488. This article has 82 citations and is from a peer-reviewed journal.
(юкина2024поискновыхиммуногистохимических pages 2-3): © М.Ю. Юкина, Е. А. Трошина, Л.С. Урусова, Нурана Фейзуллаевна Нуралиева, Лариса Вячеславовна Никанкина, В.А. Иоутси, О. Ю. Реброва, Н. Г. Мокрышева, M. Y. Yukina, E. Troshina, L. Urusova, N. Nuralieva, L. V. Nikankina, V. A. Ioutsi, O. Rebrova, and N. G. Mokrysheva. Поиск новых иммуногистохимических и циркулирующих маркеров инсулиномы. Problems of Endocrinology, 70:15-26, May 2024. URL: https://doi.org/10.14341/probl13466, doi:10.14341/probl13466. This article has 1 citations.
(li2024recurrentsmallvariants pages 1-2): Dong Li, Suzanne Jan de Beur, Cuiping Hou, Maura R.Z. Ruzhnikov, Hilary Seeley, Garry R. Cutting, Molly B. Sheridan, and Michael A. Levine. Recurrent small variants in nesp55/nespas associated with broad gnas methylation defects and pseudohypoparathyroidism type 1b. JCI Insight, Dec 2024. URL: https://doi.org/10.1172/jci.insight.185874, doi:10.1172/jci.insight.185874. This article has 4 citations and is from a domain leading peer-reviewed journal.
(юкина2024поискновыхиммуногистохимических pages 1-2): © М.Ю. Юкина, Е. А. Трошина, Л.С. Урусова, Нурана Фейзуллаевна Нуралиева, Лариса Вячеславовна Никанкина, В.А. Иоутси, О. Ю. Реброва, Н. Г. Мокрышева, M. Y. Yukina, E. Troshina, L. Urusova, N. Nuralieva, L. V. Nikankina, V. A. Ioutsi, O. Rebrova, and N. G. Mokrysheva. Поиск новых иммуногистохимических и циркулирующих маркеров инсулиномы. Problems of Endocrinology, 70:15-26, May 2024. URL: https://doi.org/10.14341/probl13466, doi:10.14341/probl13466. This article has 1 citations.
(yang2023gnaslocusbone pages 12-13): Wan Yang, Yiyi Zuo, Nuo Zhang, Kangning Wang, Runze Zhang, Ziyi Chen, and Qing He. Gnas locus: bone related diseases and mouse models. Frontiers in Endocrinology, Oct 2023. URL: https://doi.org/10.3389/fendo.2023.1255864, doi:10.3389/fendo.2023.1255864. This article has 19 citations.

Artifacts

Edison artifact artifact-00

Citations

fonin2019multifunctionalityofproteins pages 15-17
bastepe2007thegnaslocus pages 13-13
iwasaki2023thelongrangeinteraction pages 1-2
li2024recurrentsmallvariants pages 1-2
yang2023gnaslocusbone pages 1-2
raut2025contracttokill pages 1-3
bastepe2007thegnaslocus pages 1-2
yang2023gnaslocusbone pages 12-13
https://doi.org/10.1172/jci167953
https://doi.org/10.3389/fendo.2023.1255864
https://doi.org/10.1172/jci.insight.185874
https://doi.org/10.3390/ijms252010913
https://doi.org/10.14341/probl13466
https://doi.org/10.2174/138920207783406488
https://doi.org/10.1007/s00018-019-03276-1
https://doi.org/10.1007/s00018-019-03276-1,
https://doi.org/10.3389/fendo.2023.1255864,
https://doi.org/10.1172/jci167953,
https://doi.org/10.1186/s12943-025-02247-4,
https://doi.org/10.3390/ijms252010913,
https://doi.org/10.2174/138920207783406488,
https://doi.org/10.14341/probl13466,
https://doi.org/10.1172/jci.insight.185874,

📚 Additional Documentation

Notes

(GNAS-notes.md)

GNAS notes

2026-06-02

PITA context: The MONDO issue references GNAS for PITA3, but this local review is for UniProt O95467, the NESP55 product of the complex GNAS locus. This matters because many GNAS biological phenotypes belong to canonical Gs-alpha products or locus-level imprinting rather than direct NESP55 protein function.

Deep research status: Falcon deep research succeeded for GNAS and produced GNAS-deep-research-falcon.md plus an artifact table. The artifact explicitly warned that "NESP55 should not be conflated with canonical Gsalpha signaling protein products" [file:human/GNAS/GNAS-deep-research-falcon_artifacts/artifact-00.md "NESP55 should not be conflated with canonical Gsalpha signaling protein products"].

Functional summary: NESP55 is a chromogranin-like neuroendocrine secretory product. The cloning/processing paper found that the "NESP55 open reading frame encoded a hydrophilic protein" and characterized "posttranslational processing of a maternally expressed protein" [PMID:10729789 "NESP55 open reading frame encoded a hydrophilic protein"; PMID:10729789 "posttranslational processing of a maternally expressed protein"]. Pituitary adenoma IHC describes NESP55 as a "marker of the constitutive secretory pathway" with "brown finely granular cytoplasmic staining" [PMID:21584660 "marker of the constitutive secretory pathway"; PMID:21584660 "brown finely granular cytoplasmic staining"].

Annotation decisions: I kept cytoplasmic/secretory-context annotations, modified generic transport vesicle to secretory granule, and removed or over-annotation-marked Gs-alpha/locus-level phenotypes such as thermogenesis, organism growth, PTH response, and pregnancy. The PTH paper shows a deletion "that removes NESP55" and supports NESP55 as an "additional imprinting control element" [PMID:22378814 "A novel deletion of 18,988 bp that removes NESP55"; PMID:22378814 "NESP55 is an additional imprinting control element"], but that is not direct NESP55 protein activity.

📄 View Raw YAML

id: O95467
gene_symbol: GNAS
product_type: PROTEIN
status: COMPLETE
taxon:
  id: NCBITaxon:9606
  label: Homo sapiens
description: NESP55 (UniProt O95467) is a maternally expressed, chromogranin-like neuroendocrine
  secretory protein encoded by the complex GNAS locus. NESP55 is distinct from the canonical
  Gs-alpha products of the same locus; it is expressed in neuroendocrine/chromaffin lineages,
  processed into smaller peptides, and functions as a regulated secretory-granule precursor and
  marker of neuroendocrine differentiation. GNAS-locus imprinting defects involving the NESP55
  region can cause endocrine disease, but those locus-level effects are distinct from direct
  NESP55 protein activity.
alternative_products:
- name: Nesp55 {ECO:0000269|PubMed:10729789, ECO:0000269|PubMed:10749992,
  id: O95467-1
- name: XLas-1
  id: Q5JWF2-1
  sequence_note: External
- name: XLas-2
  id: Q5JWF2-2
  sequence_note: External
- name: XLas-3
  id: Q5JWF2-3
  sequence_note: External
- name: Gnas-1 {ECO:0000305} (Alpha-S2 {ECO:0000305}, GNASl)
  id: P63092-1, P04895-1
  sequence_note: External
- name: Gnas-2 {ECO:0000305} (Alpha-S1 {ECO:0000305}, GNASs)
  id: P63092-2, P04895-2
  sequence_note: External
- name: '3'
  id: P63092-3
  sequence_note: External
- name: '4'
  id: P63092-4
  sequence_note: External
existing_annotations:
- term:
    id: GO:0005576
    label: extracellular region
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  qualifier: located_in
  review:
    summary: NESP55 is a secretory precursor, so extracellular-region annotation is plausible
      for processed/secreted material but is not the most specific functional compartment.
    action: ACCEPT
    reason: NESP55 is a secretory precursor and the extracellular-region term is a valid broad
      location for processed/secreted material, although secretory granule is the more specific
      intracellular context.
    supported_by:
    - reference_id: PMID:10729789
      supporting_text: NESP55 open reading frame encoded a hydrophilic protein
    - reference_id: file:human/GNAS/GNAS-uniprot.txt
      supporting_text: May be proteolytically processed to give rise to a number of active peptides.
- term:
    id: GO:0030133
    label: transport vesicle
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  qualifier: located_in
  review:
    summary: Transport vesicle is too generic; the evidence for NESP55 points more specifically
      to neuroendocrine secretory granules/secretory pathway compartments.
    action: MODIFY
    reason: NESP55 is chromogranin-like and shows finely granular cytoplasmic staining in pituitary
      adenomas, fitting secretory granule biology better than a generic transport vesicle term.
    proposed_replacement_terms:
    - id: GO:0030141
      label: secretory granule
    supported_by:
    - reference_id: PMID:21584660
      supporting_text: marker of the constitutive secretory pathway
    - reference_id: PMID:21584660
      supporting_text: brown finely granular cytoplasmic staining
- term:
    id: GO:0071107
    label: response to parathyroid hormone
  evidence_type: IEA
  original_reference_id: GO_REF:0000002
  qualifier: involved_in
  review:
    summary: The PTH-response evidence reflects GNAS-locus imprinting and methylation effects
      rather than a direct NESP55 protein activity.
    action: MARK_AS_OVER_ANNOTATED
    reason: PMID:22378814 shows that a deletion removing NESP55 affects imprinting and PHP1B,
      but this is a regulatory-locus effect. It should not be treated as a core biological process
      of the NESP55 protein product.
    supported_by:
    - reference_id: PMID:22378814
      supporting_text: A novel deletion of 18,988 bp that removes NESP55
    - reference_id: PMID:22378814
      supporting_text: NESP55 is an additional imprinting
- term:
    id: GO:0005886
    label: plasma membrane
  evidence_type: IDA
  original_reference_id: GO_REF:0000052
  qualifier: located_in
  review:
    summary: Plasma membrane is not supported as a normal NESP55 protein location by the reviewed
      literature; NESP55 is a secretory/granin-like product.
    action: REMOVE
    reason: The evidence points to secretory granule/cytoplasmic granular staining and secretion
      rather than a plasma-membrane resident role.
    supported_by:
    - reference_id: PMID:21584660
      supporting_text: brown finely granular cytoplasmic staining
- term:
    id: GO:0120162
    label: positive regulation of cold-induced thermogenesis
  evidence_type: ISS
  original_reference_id: PMID:20374964
  qualifier: involved_in
  review:
    summary: Cold-induced thermogenesis is a Gs-alpha/adipose signaling phenotype and should not
      be assigned to the NESP55 protein product represented by O95467.
    action: REMOVE
    reason: PMID:20374964 studies Gs-alpha deficiency in adipose tissue. That is not evidence
      for NESP55 acting in cold-induced thermogenesis.
    supported_by:
    - reference_id: PMID:20374964
      supporting_text: Gsalpha plays a critical role in adipogenesis in vivo
- term:
    id: GO:0005737
    label: cytoplasm
  evidence_type: IDA
  original_reference_id: PMID:20862257
  qualifier: located_in
  review:
    summary: Cytoplasmic localization is supported as broad localization for NESP55-containing
      secretory granules and cytoplasmic immunostaining.
    action: ACCEPT
    reason: The term is broad but compatible with the granular cytoplasmic staining seen in pituitary
      adenomas and neuroendocrine/chromaffin cells.
    supported_by:
    - reference_id: PMID:21584660
      supporting_text: brown finely granular cytoplasmic staining
- term:
    id: GO:0005634
    label: nucleus
  evidence_type: IDA
  original_reference_id: PMID:20862257
  qualifier: located_in
  review:
    summary: Nuclear localization is not supported as a normal NESP55 location in the reviewed
      sources.
    action: REMOVE
    reason: The main evidence supports cytoplasmic secretory granule/neuroendocrine localization,
      not nuclear residence.
    supported_by:
    - reference_id: PMID:20862257
      supporting_text: NESP55 is a highly specific marker for chromaffin cell types during development
- term:
    id: GO:0040015
    label: negative regulation of multicellular organism growth
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  qualifier: involved_in
  review:
    summary: Negative regulation of organism growth is a broad GNAS-locus/Gs-alpha phenotype and
      not a direct NESP55 function.
    action: REMOVE
    reason: The NESP55 product is a chromogranin-like secretory precursor; growth phenotypes from
      GNAS models should not be propagated to this product without product-specific evidence.
    supported_by:
    - reference_id: file:human/GNAS/GNAS-deep-research-falcon_artifacts/artifact-00.md
      supporting_text: NESP55 should not be conflated with canonical Gsalpha signaling protein
        products.
- term:
    id: GO:0048471
    label: perinuclear region of cytoplasm
  evidence_type: IDA
  original_reference_id: PMID:21584660
  qualifier: located_in
  review:
    summary: Perinuclear cytoplasmic localization is plausible for secretory-pathway/granular
      staining but is not the core location term.
    action: KEEP_AS_NON_CORE
    reason: NESP55 is associated with neuroendocrine secretory compartments; perinuclear cytoplasm
      can be retained as broad localization evidence.
    supported_by:
    - reference_id: PMID:21584660
      supporting_text: brown finely granular cytoplasmic staining
- term:
    id: GO:0071107
    label: response to parathyroid hormone
  evidence_type: IMP
  original_reference_id: PMID:22378814
  qualifier: involved_in
  review:
    summary: The PTH-response evidence reflects GNAS-locus imprinting and methylation effects
      rather than a direct NESP55 protein activity.
    action: MARK_AS_OVER_ANNOTATED
    reason: PMID:22378814 shows that a deletion removing NESP55 affects imprinting and PHP1B,
      but this is a regulatory-locus effect. It should not be treated as a core biological process
      of the NESP55 protein product.
    supported_by:
    - reference_id: PMID:22378814
      supporting_text: A novel deletion of 18,988 bp that removes NESP55
    - reference_id: PMID:22378814
      supporting_text: NESP55 is an additional imprinting
- term:
    id: GO:0007565
    label: female pregnancy
  evidence_type: NAS
  original_reference_id: PMID:10729789
  qualifier: involved_in
  review:
    summary: Female pregnancy is not supported as a direct process for the NESP55 protein product.
    action: REMOVE
    reason: The cited NESP55 cloning/processing paper describes a neuroendocrine secretory protein
      and tissue-specific splicing, not a direct pregnancy function.
    supported_by:
    - reference_id: PMID:10729789
      supporting_text: NESP55 open reading frame encoded a hydrophilic protein
- term:
    id: GO:0009306
    label: protein secretion
  evidence_type: NAS
  original_reference_id: PMID:10729789
  qualifier: involved_in
  review:
    summary: NESP55 is a secretory protein/cargo, but the available evidence does not show that
      it actively mediates protein secretion.
    action: MARK_AS_OVER_ANNOTATED
    reason: A secreted or processed cargo should not automatically receive a protein secretion
      process annotation as if it controls secretion machinery.
    supported_by:
    - reference_id: PMID:10729789
      supporting_text: posttranslational processing of a maternally expressed protein
    - reference_id: PMID:21584660
      supporting_text: marker of the constitutive secretory pathway
references:
- id: GO_REF:0000002
  title: Gene Ontology annotation through association of InterPro records with GO terms
  findings: []
- id: GO_REF:0000024
  title: Manual transfer of experimentally-verified manual GO annotation data to orthologs by
    curator judgment of sequence similarity
  findings: []
- id: GO_REF:0000044
  title: Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location vocabulary
    mapping, accompanied by conservative changes to GO terms applied by UniProt
  findings: []
- id: GO_REF:0000052
  title: Gene Ontology annotation based on curation of immunofluorescence data
  findings: []
- id: PMID:10729789
  title: 'Neuroendocrine secretory protein 55 (NESP55): alternative splicing onto transcripts
    of the GNAS gene and posttranslational processing of a maternally expressed protein.'
  findings: []
- id: PMID:20374964
  title: "G(s)alpha deficiency in adipose tissue leads to a lean phenotype with divergent effects on cold tolerance and diet-induced thermogenesis."
  findings: []
- id: PMID:20862257
  title: "Differentiation in neuroblastoma: diffusion-limited hypoxia induces neuro-endocrine secretory protein 55 and other markers of a chromaffin phenotype."
  findings: []
- id: PMID:21584660
  title: Immunohistochemical expression of neuroendocrine secretory protein-55 (NESP-55) in pituitary
    adenomas.
  findings: []
- id: PMID:22378814
  title: A new deletion ablating NESP55 causes loss of maternal imprint of A/B GNAS and autosomal
    dominant pseudohypoparathyroidism type Ib.
  findings: []
- id: file:human/GNAS/GNAS-uniprot.txt
  title: UniProt record for GNAS/NESP55
  findings: []
- id: file:human/GNAS/GNAS-deep-research-falcon_artifacts/artifact-00.md
  title: Falcon deep research artifact for GNAS/NESP55
  findings: []
core_functions:
- description: NESP55 acts as a chromogranin-like neuroendocrine secretory precursor in chromaffin/neuroendocrine
    cells, undergoing post-translational processing and marking secretory-granule differentiation
    rather than catalyzing a defined biochemical reaction.
  locations:
  - id: GO:0030141
    label: secretory granule
  - id: GO:0005576
    label: extracellular region
  supported_by:
  - reference_id: PMID:10729789
    supporting_text: NESP55 open reading frame encoded a hydrophilic protein
  - reference_id: PMID:10729789
    supporting_text: posttranslational processing of a maternally expressed protein
  - reference_id: PMID:21584660
    supporting_text: marker of the constitutive secretory pathway
  - reference_id: PMID:20862257
    supporting_text: NESP55 is a highly specific marker for chromaffin cell types during development
proposed_new_terms: []
suggested_questions:
- question: Which processed NESP55 peptides have reproducible physiological activity in human
    neuroendocrine tissues?
- question: Can GNAS annotations be separated more cleanly by product so that NESP55-specific
    annotations are not mixed with Gs-alpha signaling phenotypes?
suggested_experiments:
- description: Use isoform/product-specific antibodies or tagged endogenous NESP55 to define secretory
    granule localization and secretion dynamics in neuroendocrine cells.
  hypothesis: NESP55 will localize to regulated secretory compartments and be secreted or processed
    in neuroendocrine cells.
- description: Profile processed NESP55 peptides by targeted mass spectrometry in pituitary, adrenal
    medulla, and neuroendocrine tumor samples.
  hypothesis: Product-specific peptide profiling will identify which NESP55-derived peptides are
    reproducibly produced in relevant tissues.

GNAS

Gene Description

Existing Annotations Review

Core Functions

NESP55 acts as a chromogranin-like neuroendocrine secretory precursor in chromaffin/neuroendocrine cells, undergoing post-translational processing and marking secretory-granule differentiation rather than catalyzing a defined biochemical reaction.

References

Suggested Questions for Experts

Suggested Experiments

Deep Research

Falcon

Research Report: Human GNAS locus product NESP55 (UniProt O95467)—functional annotation

0) Target verification (critical disambiguation)

1) Key concepts and current definitions

1.1 The GNAS locus as a “complex/imprinted” gene

1.2 What NESP55 is (and is not)

2) Molecular function: biochemical nature, processing, and inferred mechanism

2.1 Precursor and peptide processing

2.2 Subcellular localization and secretion context

3) Expression and localization in tissues (current evidence)

4) Pathways and regulatory biology (recent developments prioritized)

4.1 Imprinting control of NESP55 (2023 mechanistic advance)

4.2 NESP55/NESPAS region variants and pseudohypoparathyroidism type 1B (2024 genetic advance)

5) Current applications and real-world implementations

5.1 Tumor marker exploration in pancreatic neuroendocrine tumors (P‑NETs) and insulinoma

5.2 Clinical genetics / diagnostics relevance via imprinting

6) Relevant statistics and recent data points (explicitly evidenced)

7) Expert synthesis and evidence gaps

Evidence summary table

Key references (with URLs and publication dates)

Artifacts

Citations

📚 Additional Documentation

Notes

GNAS notes

2026-06-02

📄 View Raw YAML